首页 > 最新文献

Current Controlled Trials in Cardiovascular Medicine最新文献

英文 中文
Are there fundamental deficiencies in the megatrial methodology? 巨心房方法学是否存在根本性缺陷?
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-02-09 DOI: 10.1186/cvm-2-1-001
D. Julian, C. Furberg
{"title":"Are there fundamental deficiencies in the megatrial methodology?","authors":"D. Julian, C. Furberg","doi":"10.1186/cvm-2-1-001","DOIUrl":"https://doi.org/10.1186/cvm-2-1-001","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"37 1","pages":"1 - 1"},"PeriodicalIF":0.0,"publicationDate":"2001-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88620587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
New immunosuppressive drugs in heart transplantation 新型免疫抑制药物在心脏移植中的应用
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-02-08 DOI: 10.1186/cvm-2-1-045
M. Costanzo
{"title":"New immunosuppressive drugs in heart transplantation","authors":"M. Costanzo","doi":"10.1186/cvm-2-1-045","DOIUrl":"https://doi.org/10.1186/cvm-2-1-045","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"24 1","pages":"45 - 53"},"PeriodicalIF":0.0,"publicationDate":"2001-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88353516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Experience collecting interim data on mortality: an example from the RALES study 收集死亡率临时数据的经验:以RALES研究为例
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-02-07 DOI: 10.1186/cvm-2-1-059
J. Wittes, J. Palensky, Debra J. Asner, D. Julian, J. Boissel, C. Furberg, H. Kulbertus, S. Pocock, B. Roniker
{"title":"Experience collecting interim data on mortality: an example from the RALES study","authors":"J. Wittes, J. Palensky, Debra J. Asner, D. Julian, J. Boissel, C. Furberg, H. Kulbertus, S. Pocock, B. Roniker","doi":"10.1186/cvm-2-1-059","DOIUrl":"https://doi.org/10.1186/cvm-2-1-059","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"29 1","pages":"59 - 62"},"PeriodicalIF":0.0,"publicationDate":"2001-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75759262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
The Proliferation REduction with Vascular ENergy Trial (PREVENT) 血管能量抑制增殖试验(PREVENT)
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-02-01 DOI: 10.1186/cvm-2-1-016
A. Raizner, G. Kaluza
{"title":"The Proliferation REduction with Vascular ENergy Trial (PREVENT)","authors":"A. Raizner, G. Kaluza","doi":"10.1186/cvm-2-1-016","DOIUrl":"https://doi.org/10.1186/cvm-2-1-016","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"5 1","pages":"16 - 19"},"PeriodicalIF":0.0,"publicationDate":"2001-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74813137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Fundamental deficiencies in the megatrial methodology 巨心房方法学的根本缺陷
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-01-30 DOI: 10.1186/cvm-2-1-002
B. Charlton
{"title":"Fundamental deficiencies in the megatrial methodology","authors":"B. Charlton","doi":"10.1186/cvm-2-1-002","DOIUrl":"https://doi.org/10.1186/cvm-2-1-002","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"68 1","pages":"2 - 7"},"PeriodicalIF":0.0,"publicationDate":"2001-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90921406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 31
Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials 磁共振扩散和灌注成像在急性脑卒中临床试验中的应用
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-01-30 DOI: 10.1186/cvm-2-1-038
S. Warach
{"title":"Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials","authors":"S. Warach","doi":"10.1186/cvm-2-1-038","DOIUrl":"https://doi.org/10.1186/cvm-2-1-038","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"14 1","pages":"38 - 44"},"PeriodicalIF":0.0,"publicationDate":"2001-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87178425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 51
The current status of primary prevention in coronary heart disease. 冠心病一级预防的现状。
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-01-01 DOI: 10.1186/cvm-2-1-024
Cornel Pater

During the second part of the twentieth century, research advances caused a substantial decline in the rate of coronary heart disease. The decline lasted from the mid-1960s until the early 1990s and occurred primarily in Western countries. However, an unfavourable trend in coronary heart disease related mortality has gradually developed during the 1990s, with cardiovascular diseases anticipated to remain the main cause of overall mortality for the foreseeable future. The present paper aims at analyzing the current status of the main determinants of population-wide coronary heart disease prevention.

在二十世纪下半叶，研究进展导致冠心病发病率大幅下降。这种衰退从20世纪60年代中期一直持续到90年代初，主要发生在西方国家。然而，在20世纪90年代，与冠心病相关的死亡率逐渐出现了不利趋势，预计在可预见的未来，心血管疾病仍将是总体死亡率的主要原因。本文旨在分析人群冠心病预防的主要决定因素的现状。
{"title":"The current status of primary prevention in coronary heart disease.","authors":"Cornel Pater","doi":"10.1186/cvm-2-1-024","DOIUrl":"https://doi.org/10.1186/cvm-2-1-024","url":null,"abstract":"<p><p>During the second part of the twentieth century, research advances caused a substantial decline in the rate of coronary heart disease. The decline lasted from the mid-1960s until the early 1990s and occurred primarily in Western countries. However, an unfavourable trend in coronary heart disease related mortality has gradually developed during the 1990s, with cardiovascular diseases anticipated to remain the main cause of overall mortality for the foreseeable future. The present paper aims at analyzing the current status of the main determinants of population-wide coronary heart disease prevention.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"2 1","pages":"24-37"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/cvm-2-1-024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Arterial indications for the low molecular weight heparins. 低分子肝素的动脉适应症。
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-01-01 DOI: 10.1186/cvm-2-5-233
Walter Ageno, Menno V Huisman

Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the low molecular weight heparins (LMWHs) are at least as effective as unfractionated heparin. The LMWHs are easier to use, with the potential to facilitate long-term outpatient treatment. The results of the trials have actually failed to show any clear advantage, however, of the LMWHs over the standard antiplatelet treatment, despite the evidence of a sustained hypercoagulability. Potentially, the use of higher doses of LMWHs could improve the outcomes, but this is as yet unproven and could be associated with unacceptably increased risk of bleeding. During the acute phase of a stroke, aspirin is the first choice of antithrombotic drug because it reduces the risk of recurrent stroke. LMWH cannot be recommended as an antithrombotic agent for the acute treatment of stroke. Prophylactic use of low dose LMWH for the prevention of venous thromboembolism should be considered in every patient with a stroke.

抗血栓治疗在急性冠状动脉综合征患者中具有重要意义。目前，在不稳定型心绞痛患者的几项临床试验中积累的证据表明，低分子肝素（LMWHs）至少与普通肝素一样有效。LMWH更容易使用，有可能促进长期门诊治疗。然而，尽管有证据表明LMWHs具有持续的高凝状态，但试验结果实际上并没有显示出任何明显的优于标准抗血小板治疗的优势。使用更高剂量的低分子肝素可能会改善预后，但这一点尚未得到证实，可能会导致出血风险增加，令人无法接受。在中风急性期，阿司匹林是抗血栓药物的首选，因为它可以降低复发中风的风险。不能推荐低分子肝素作为中风急性治疗的抗血栓药物。每一位中风患者都应考虑预防性使用低剂量低分子肝素预防静脉血栓栓塞。
{"title":"Arterial indications for the low molecular weight heparins.","authors":"Walter Ageno,&nbsp;Menno V Huisman","doi":"10.1186/cvm-2-5-233","DOIUrl":"https://doi.org/10.1186/cvm-2-5-233","url":null,"abstract":"<p><p>Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the low molecular weight heparins (LMWHs) are at least as effective as unfractionated heparin. The LMWHs are easier to use, with the potential to facilitate long-term outpatient treatment. The results of the trials have actually failed to show any clear advantage, however, of the LMWHs over the standard antiplatelet treatment, despite the evidence of a sustained hypercoagulability. Potentially, the use of higher doses of LMWHs could improve the outcomes, but this is as yet unproven and could be associated with unacceptably increased risk of bleeding. During the acute phase of a stroke, aspirin is the first choice of antithrombotic drug because it reduces the risk of recurrent stroke. LMWH cannot be recommended as an antithrombotic agent for the acute treatment of stroke. Prophylactic use of low dose LMWH for the prevention of venous thromboembolism should be considered in every patient with a stroke.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"2 5","pages":"233-239"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/cvm-2-5-233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Dose response of ACE inhibitors: implications of the SECURE trial. ACE抑制剂的剂量反应：SECURE试验的意义。
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2001-01-01 DOI: 10.1186/cvm-2-4-155
Eva Lonn

The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure.

在临床实践中选择合适的ACE抑制剂剂量是一个重要的问题。现有证据表明，在慢性心力衰竭和慢性冠状动脉疾病中，高剂量的血管紧张素转换酶（ACE）抑制剂比低剂量的更有效。目前推荐的临床方法是靶向ACE抑制剂给药方案，与临床试验中使用的方案相似，这证明了死亡率和发病率的益处。当适当滴定时，ACE抑制剂通常具有良好的耐受性，并且在大多数患有动脉粥样硬化性血管疾病的患者中，无论是否患有心力衰竭，都可以达到并保持目标剂量。
{"title":"Dose response of ACE inhibitors: implications of the SECURE trial.","authors":"Eva Lonn","doi":"10.1186/cvm-2-4-155","DOIUrl":"10.1186/cvm-2-4-155","url":null,"abstract":"<p><p>The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure.</p>","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"2 4","pages":"155-159"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'No independent link' between diabetes and poor outcomes after CABG/PTCA CABG/PTCA术后不良预后与糖尿病之间无独立联系
Current Controlled Trials in Cardiovascular Medicine
Pub Date : 2000-12-07 DOI: 10.1186/CVM-2001-72154
J. Lyford
{"title":"'No independent link' between diabetes and poor outcomes after CABG/PTCA","authors":"J. Lyford","doi":"10.1186/CVM-2001-72154","DOIUrl":"https://doi.org/10.1186/CVM-2001-72154","url":null,"abstract":"","PeriodicalId":53230,"journal":{"name":"Current Controlled Trials in Cardiovascular Medicine","volume":"19 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2000-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82534073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Current Controlled Trials in Cardiovascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1